全球基因檢測板市場

全球基因檢測晶片市場預計到2030年將達到99億美元

全球基因檢測市場規模在2024年估計為34億美元，預計2030年將達到99億美元，在分析期間（2024-2030年）內複合年成長率（CAGR）為19.7%。本報告分析的細分市場之一—「癌症風險評估」應用領域，預計將以21.2%的複合年成長率成長，並在分析期結束時達到48億美元。此外，「先天性疾病診斷」應用領域預計在分析期間內將以19.5%的複合年成長率成長。

美國市場規模估計為9.162億美元，而中國市場預計將以18.2%的複合年成長率成長。

預計到2024年，美國基因檢測市場規模將達到9.162億美元。作為世界第二大經濟體，中國預計到2030年市場規模將達到15億美元，在2024年至2030年的分析期間內，複合年成長率（CAGR）將達到18.2%。其他值得關注的區域市場包括日本和加拿大，預計在分析期內，這兩個市場的複合年成長率將分別達到18.1%和16.7%。在歐洲，德國的複合年成長率預計將達到約13.9%。

全球基因檢測市場—關鍵趨勢與促進因素概述

為什麼基因組檢測在現代基因組醫學中至關重要？

基因檢測已成為現代基因組醫學中不可或缺的工具，徹底改變了遺傳性疾病、癌症和先天性疾病的診斷和治療方式。那麼，基因檢測為何如此重要？基因檢測是一種定序定序，專注於與特定疾病或病症相關的特定基因。與分析整個基因組的全基因測序不同，基因檢測聚焦於已知與特定疾病相關的基因，從而實現更具針對性、更經濟高效且更快速的分析。這種精準性對於醫療服務提供者至關重要，能夠幫助他們更快、更準確地做出診斷，並制定個人化的治療方案。

例如，在腫瘤學領域，基因檢測可用於識別癌症相關基因的突變，並根據腫瘤的基因組成製定個人化治療方法。 BRCA1 和 BRCA2 等基因的突變顯示乳癌或卵巢癌的風險更高，並可指南預防措施或特定治療。在其他領域，例如心臟病學和神經病學，基因檢測有助於識別遺傳性心臟疾病、神經退化性疾病或兒童發育遲緩的遺傳病因。透過聚焦於疾病特異性基因，基因檢測提供了一種高度標靶的方法來了解遺傳因素，從而實現更有效、更個人化的醫療解決方案。

科技進步如何提升基因檢測組合的效能？

技術進步顯著提升了基因panel的性能、準確性和可用性，進一步增強了其在臨床和研究領域的價值。其中最具影響力的進步之一是次世代定序（NGS）技術的發展，它徹底革新了基因體學領域。 NGS能夠在一次檢測中並行定序多個基因，與傳統定序方法相比，能夠以更低的成本和更短的時間提供快速、全面的遺傳數據。這使得基因panel更加經濟實惠且易於獲取，從而得以在臨床診斷，特別是精準醫療領域得到廣泛應用。

另一項關鍵創新是用於解讀基因組數據的生物資訊學工具的進步。鑑於新一代定序（NGS）產生的數據量龐大，先進的生物資訊演算法對於識別致病變異、排除良性變異以及評估基因觀察的臨床意義至關重要。這些工具能夠幫助臨床醫生根據基因組檢測結果做出更明智的決策，進而提高診斷準確性和治療效果。此外，雲端基礎的數據儲存和分析平台使醫療服務提供者能夠即時存取和分析基因數據，從而簡化診斷實驗室的工作流程並提高基因檢測的效率。

此外，基因檢測技術的進步使得基因檢測更加個人化和全面。現在可以根據特定患者的症狀、家族病史和疾病風險，設計客製化的基因檢測方案，並專注於相關的基因組。這些方案還可以擴展和完善，納入新的遺傳標記和最新的疾病相關基因研究成果。這種靈活性在罕見疾病研究中尤其重要，因為它可以設計針對罕見基因變異的客製化基因檢測方案，這些罕見基因變異可能與患者的病情有關。這些技術進步提高了基因檢測的準確性、速度和靈活性，使基因檢測更加有效，並廣泛應用於多個醫學領域。

為什麼基因檢測對個人化醫療和早期檢測至關重要？

基因檢測在個人化醫療中發揮著至關重要的作用，它能提供精準的基因訊息，從而為每位患者量身定做治療方案。基因檢測的關鍵優勢之一在於其能夠識別與疾病相關的特定突變或變異，使醫療專業人員能夠做出更明智的患者照護決策。例如，在癌症治療中，基因檢測可以檢測驅動腫瘤生長的基因突變，例如肺癌中的EGFR突變和結直腸癌中的KRAS突變。掌握這些資訊後，腫瘤科醫師可以針對特定的基因譜系製定更有效的標靶治療，從而改善患者預後並降低副作用風險。

基因檢測對於早期發現和預防遺傳性疾病至關重要。對於有遺傳性疾病或癌症家族病史的個體，基因檢測可以辨識BRCA1和BRCA2等基因的突變。這些突變與乳癌、卵巢和其他癌症的風險增加有關。早期發現這些突變有助於採取積極措施，例如強化後續觀察、改變生活方式和預防性手術，從而降低患病風險。同樣，用於產前和孕前檢測的基因檢測可以識別囊腫纖維化和戴-薩克斯病等遺傳性疾病的攜帶者狀態，使家庭能夠做出知情的生育決定。

除了癌症之外，基因檢測在心臟病學領域也被廣泛應用，用於檢測與遺傳性心臟病（例如肥厚型心肌病和致心律失常性右室心肌病變）相關的基因突變。早期識別這些遺傳標記有助於更密切的監測、早期療育和個人化治療，從而預防諸如心臟麻痹等併發症。由於基因檢測能夠在症狀出現之前或疾病早期階段檢測到基因突變，因此它們是疾病預防、早期療育和個體化治療策略中不可或缺的工具，能夠確保患者根據其基因組成獲得最有效的治療。

哪些因素正在推動基因檢測市場的成長？

基因檢測市場正經歷快速成長，這主要得益於幾個關鍵因素，包括基因檢測技術的進步、個人化醫療需求的不斷成長以及遺傳疾病盛行率的上升。首先，次世代定序（NGS）技術的發展徹底改變了基因檢測市場。 NGS顯著降低了多基因定序的成本和時間，使基因檢測更加經濟實惠，也更容易被更廣泛的醫療服務提供者和患者所接受。這促使基因檢測在臨床實務上已廣泛應用，如今已廣泛應用於診斷、腫瘤學、心臟病學、罕見疾病研究等領域。

其次，對個人化醫療日益成長的需求是基因檢測市場的主要驅動力。隨著醫療保健朝著更個人化的治療方式發展，基於患者基因譜客製化治療方法的能力變得愈發重要。基因檢測能夠提供做出明智治療決策所需的特定基因訊息，尤其是在癌症治療中，可以根據患者的基因突變選擇標靶治療。這種對精準醫療的需求正在推動基因檢測的研究和臨床應用，使治療更加個人化和有效。

第三，遺傳性疾病和癌症的日益普遍推動了基因檢測需求的成長。癌症、心血管疾病、神經退化性疾病和其他疾病發生率的上升，促使人們更需要早期檢測和精準診斷。基因檢測為識別與這些疾病相關的遺傳風險因素和突變提供了強力的工具，從而實現早期療育並改善患者預後。此外，基因檢測也廣​​泛應用於產前檢測，能夠檢測胎兒的基因異常，從而實現早期診斷並為潛在的健康問題做好準備。

此外，監管核准和日益增強的醫學意識正在推動市場成長。隨著各國政府和醫療機構越來越認知到基因檢測的價值，用於臨床的基因檢測組合的核准也不斷增加。這促進了基因檢測的普及，並擴大了其在主流醫療保健領域的應用範圍。大眾對基因檢測及其益處的認知不斷提高，也推動了市場需求，因為患者越來越希望了解自身的遺傳健康風險和治療方案。

最後，面向消費者的基因檢測（DTC）的興起也推動了基因檢測組合市場的擴張。提供祖源、健康風險和攜帶者狀態等基因檢測服務的公司正擴大將基因檢測組合納入其服務範圍，使基因檢測能夠更廣泛地惠及大眾。隨著越來越多的人能夠獲得個人化的基因資訊來指南其醫療決策，這一趨勢正在進一步擴大市場。

總之，基因檢測市場成長的促進因素包括：次世代定序技術的進步、個人化醫療需求的不斷成長、遺傳疾病盛行率的上升、監管支持以及面向消費者的基因檢測的普及。隨著基因檢測日益融入常規醫療保健，基因檢測將在推動診斷進步、個人化治療和疾病預防方面繼續發揮關鍵作用，其應用範圍涵蓋廣泛的醫療保健領域。

部分：

產品/服務（檢測套組、檢測服務），用途（癌症風險評估、先天性疾病診斷、藥物基因學、其他用途），最終用戶（醫院/診斷實驗室、製藥/生物技術公司、研究/學術機構）

受訪公司範例

• Agilent Technologies, Inc.
• ArcherDX, Inc.
• Eurofins Scientific SE
• F. Hoffmann-La Roche AG
• GATC Biotech AG
• GENEWIZ
• Illumina, Inc.
• Integrated DNA Technologies（IDT）, Inc.
• Personalis, Inc.
• QIAGEN GmbH
• Thermo Fisher Scientific, Inc.

人工智慧整合

我們正在利用檢驗的專家內容和人工智慧工具，革新市場和競爭情報分析。

Market Glass, Inc. 並沒有查詢LLM 或產業專用的SLM 的典型方法，而是建立了一個由世界各地領域專家精心策劃的內容庫，其中包括影片轉錄、BLOG、搜尋引擎研究以及大量的公司、產品/服務和市場數據。

關稅影響係數

在最新發布的報告中，Market Glass, Inc. 將關稅對地理市場的影響納入考量，並根據公司總部所在國、製造地以及進出口（成品和OEM產品）情況，預測企業競爭格局的變化。這種複雜多變的市場現實將對競爭對手產生多方面的影響，包括銷貨成本增加、盈利下降和供應鏈重組，同時也會影響微觀和宏觀市場動態。

目錄

第1章調查方法

第2章執行摘要

• 市場概覽
• 主要企業
• 市場趨勢和促進因素
• 全球市場展望

第3章 市場分析

• 美國
• 加拿大
• 日本
• 中國
• 歐洲
• 法國
• 德國
• 義大利
• 英國
• 其他歐洲
• 亞太地區
• 世界其他地區

第4章 競賽

Global Gene Panel Market to Reach US$9.9 Billion by 2030

The global market for Gene Panel estimated at US$3.4 Billion in the year 2024, is expected to reach US$9.9 Billion by 2030, growing at a CAGR of 19.7% over the analysis period 2024-2030. Cancer Risk Assessment Application, one of the segments analyzed in the report, is expected to record a 21.2% CAGR and reach US$4.8 Billion by the end of the analysis period. Growth in the Diagnosis of Congenital Diseases Application segment is estimated at 19.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$916.2 Million While China is Forecast to Grow at 18.2% CAGR

The Gene Panel market in the U.S. is estimated at US$916.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.5 Billion by the year 2030 trailing a CAGR of 18.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 18.1% and 16.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.9% CAGR.

Global Gene Panel Market - Key Trends and Drivers Summarized

Why Are Gene Panels Essential in Modern Genomic Medicine?

Gene panels have become an indispensable tool in modern genomic medicine, revolutionizing how genetic disorders, cancers, and inherited diseases are diagnosed and treated. But why are gene panels so crucial today? Gene panels are targeted sequencing tests that focus on a specific set of genes related to a particular disease or medical condition. Unlike whole-genome sequencing, which analyzes the entire genome, gene panels allow for a more focused, cost-effective, and quicker analysis by honing in on genes known to be associated with certain diseases. This precision is essential for healthcare providers in making faster, more accurate diagnoses and guiding personalized treatment plans.

In oncology, for instance, gene panels are used to identify mutations in cancer-related genes, allowing oncologists to tailor treatments based on the genetic makeup of a patient's tumor. For example, mutations in genes like BRCA1 and BRCA2 can indicate a higher risk for breast or ovarian cancer, guiding preventive measures or specific therapies. In other fields, such as cardiology and neurology, gene panels help identify the genetic causes of inherited heart diseases, neurodegenerative disorders, or developmental delays in children. By focusing on disease-specific genes, gene panels offer a highly targeted approach to understanding genetic factors, allowing for more effective and personalized healthcare solutions.

How Are Technological Advancements Enhancing the Performance of Gene Panels?

Technological advancements are significantly enhancing the performance, accuracy, and accessibility of gene panels, making them even more valuable in both clinical and research settings. One of the most impactful advancements is the development of next-generation sequencing (NGS) technology, which has revolutionized the field of genomics. NGS allows for the parallel sequencing of multiple genes in a single test, providing fast, comprehensive genetic data at a fraction of the cost and time compared to older sequencing methods. This has made gene panels more affordable and accessible, enabling widespread use in clinical diagnostics, especially in personalized medicine.

Another important innovation is the refinement of bioinformatics tools used to interpret gene panel data. With the vast amount of data generated by NGS, advanced bioinformatics algorithms are critical for identifying pathogenic variants, filtering out benign mutations, and assessing the clinical significance of genetic findings. These tools help clinicians make more informed decisions based on the results of gene panels, leading to improved diagnostic accuracy and treatment outcomes. Additionally, cloud-based data storage and analysis platforms now allow healthcare providers to access and analyze genetic data in real time, streamlining the workflow for diagnostic labs and making genetic testing more efficient.

Further, advancements in gene panel design are enabling more customizable and comprehensive testing. Custom panels can now be tailored to focus on specific sets of genes relevant to a particular patient’s symptoms, family history, or disease risks. These panels can be expanded or refined to include emerging genetic markers or the latest discoveries in disease-related genes. This flexibility is particularly useful in rare disease research, where custom gene panels can be designed to target less common genetic mutations that may be relevant to a patient’s condition. By improving the precision, speed, and flexibility of gene panels, these technological advancements are making genetic testing more effective and widely applicable across multiple medical fields.

Why Are Gene Panels Critical for Personalized Medicine and Early Detection?

Gene panels play a pivotal role in personalized medicine, providing the precise genetic information needed to tailor treatments to individual patients. One of the key advantages of gene panels is their ability to identify specific mutations or variants associated with diseases, allowing healthcare providers to make more informed decisions about patient care. In cancer treatment, for instance, gene panels can detect mutations in genes that drive tumor growth, such as EGFR in lung cancer or KRAS in colorectal cancer. With this information, oncologists can prescribe targeted therapies that are more likely to be effective for a particular genetic profile, improving patient outcomes and reducing the risk of side effects.

Gene panels are also essential for early detection and prevention of hereditary diseases. In individuals with a family history of genetic disorders or cancer, gene panels can identify mutations in genes like BRCA1 or BRCA2, which are linked to an increased risk of breast, ovarian, and other cancers. Early detection of such mutations allows for proactive measures, such as enhanced surveillance, lifestyle changes, or preventive surgeries, to reduce the risk of developing the disease. Similarly, gene panels used in prenatal and preconception testing can identify carrier status for inherited conditions like cystic fibrosis or Tay-Sachs disease, enabling families to make informed reproductive decisions.

In addition to cancer, gene panels are widely used in cardiology to detect mutations linked to inherited heart conditions, such as hypertrophic cardiomyopathy or arrhythmogenic right ventricular dysplasia. Early identification of these genetic markers allows for closer monitoring, early intervention, and personalized treatments to prevent complications like sudden cardiac arrest. The ability of gene panels to detect genetic mutations before symptoms appear or in the early stages of disease makes them invaluable tools for disease prevention, early intervention, and personalized treatment strategies, ensuring that patients receive the most effective care based on their genetic makeup.

What Factors Are Driving the Growth of the Gene Panel Market?

The gene panel market is experiencing rapid growth, driven by several key factors, including advancements in genetic testing technologies, the increasing demand for personalized medicine, and the rising prevalence of genetic and hereditary diseases. First, the development of next-generation sequencing (NGS) technology has been a game-changer for the gene panel market. NGS has significantly reduced the cost and time required to sequence multiple genes, making gene panels more affordable and accessible to a wider range of healthcare providers and patients. This has expanded the use of gene panels in clinical settings, where they are now commonly used in diagnostics, oncology, cardiology, and rare disease research.

Second, the growing demand for personalized medicine is a major driver of the gene panel market. As healthcare shifts toward more individualized treatment approaches, the ability to tailor therapies based on a patient’s genetic profile is becoming increasingly important. Gene panels provide the specific genetic information needed to make informed treatment decisions, particularly in cancer, where targeted therapies can be matched to a patient’s genetic mutations. This demand for precision medicine is driving the adoption of gene panels in both research and clinical settings, as they allow for more personalized and effective care.

Third, the increasing prevalence of genetic disorders and cancers is contributing to the rising demand for gene panels. With the growing incidence of diseases like cancer, cardiovascular disorders, and neurodegenerative diseases, there is a heightened need for early detection and accurate diagnosis. Gene panels offer a powerful tool for identifying genetic risk factors and mutations associated with these diseases, enabling early intervention and improved patient outcomes. Additionally, gene panels are widely used in prenatal testing, where they can detect genetic abnormalities in fetuses, allowing for early diagnosis and preparation for potential health issues.

Moreover, regulatory approvals and growing healthcare awareness are accelerating market growth. As governments and healthcare organizations increasingly recognize the value of genetic testing, more gene panels are receiving regulatory approval for clinical use. This is making genetic testing more widely available and expanding its use in mainstream healthcare. Increased public awareness about genetic testing and its benefits is also driving demand, as patients seek more information about their genetic health risks and treatment options.

Lastly, the rise of direct-to-consumer (DTC) genetic testing services is contributing to the expansion of the gene panel market. Companies offering consumer-accessible genetic tests for ancestry, health risks, and carrier status are increasingly incorporating gene panels into their offerings, making genetic testing more widely available to the general public. This trend is further expanding the market as more individuals gain access to personalized genetic information that can guide their healthcare decisions.

In conclusion, the growth of the gene panel market is being driven by advancements in next-generation sequencing, the increasing demand for personalized medicine, the rising prevalence of genetic diseases, regulatory support, and the expansion of direct-to-consumer genetic testing. As genetic testing becomes more integrated into everyday healthcare, gene panels will continue to play a crucial role in advancing diagnostics, personalized treatment, and disease prevention across a wide range of medical fields.

SCOPE OF STUDY:

The report analyzes the Gene Panel market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product & Service (Test Kits, Testing Services); Application (Cancer Risk Assessment, Diagnosis of Congenital Diseases, Pharmacogenetics, Other Applications); End-Use (Hospital & Diagnostic Laboratories, Pharma & Biotech Companies, Research & Academic Institutes)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 47 Featured) -

• Agilent Technologies, Inc.
• ArcherDX, Inc.
• Eurofins Scientific SE
• F. Hoffmann-La Roche AG
• GATC Biotech AG
• GENEWIZ
• Illumina, Inc.
• Integrated DNA Technologies (IDT), Inc.
• Personalis, Inc.
• QIAGEN GmbH
• Thermo Fisher Scientific, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
  • Global Economic Update
  • Gene Panel - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Surge in Genetic Testing and Personalized Medicine Boosts Demand for Gene Panels
  • Advances in Next-Generation Sequencing (NGS) Technologies Enhance Gene Panel Accuracy
  • Growth in Oncology Research Drives Adoption of Cancer-Specific Gene Panels
  • Role of Gene Panels in Rare Disease Diagnosis and Treatment Strategies
  • Market Opportunities in Prenatal and Newborn Screening Applications
  • Consumer Demand for Direct-to-Consumer Genetic Testing Kits
  • Role of Gene Panels in Pharmacogenomics and Drug Response Profiling
  • Impact of Artificial Intelligence and Machine Learning on Gene Panel Development
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for Cancer Risk Assessment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 2: World 6-Year Perspective for Cancer Risk Assessment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 3: World Recent Past, Current & Future Analysis for Diagnosis of Congenital Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 4: World 6-Year Perspective for Diagnosis of Congenital Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Pharmacogenetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World 6-Year Perspective for Pharmacogenetics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 7: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 8: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 9: World Recent Past, Current & Future Analysis for Test Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 10: World 6-Year Perspective for Test Kits by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Testing Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World 6-Year Perspective for Testing Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 13: World Recent Past, Current & Future Analysis for Hospital & Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 14: World 6-Year Perspective for Hospital & Diagnostic Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 15: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 16: World 6-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Research & Academic Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World 6-Year Perspective for Research & Academic Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 19: World Gene Panel Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Gene Panel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World 6-Year Perspective for Gene Panel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Gene Panel Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 22: USA Recent Past, Current & Future Analysis for Gene Panel by Application - Cancer Risk Assessment, Diagnosis of Congenital Diseases, Pharmacogenetics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 23: USA 6-Year Perspective for Gene Panel by Application - Percentage Breakdown of Value Sales for Cancer Risk Assessment, Diagnosis of Congenital Diseases, Pharmacogenetics and Other Applications for the Years 2025 & 2030
  • TABLE 24: USA Recent Past, Current & Future Analysis for Gene Panel by Product & Service - Test Kits and Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 25: USA 6-Year Perspective for Gene Panel by Product & Service - Percentage Breakdown of Value Sales for Test Kits and Testing Services for the Years 2025 & 2030
  • TABLE 26: USA Recent Past, Current & Future Analysis for Gene Panel by End-Use - Hospital & Diagnostic Laboratories, Pharma & Biotech Companies and Research & Academic Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 27: USA 6-Year Perspective for Gene Panel by End-Use - Percentage Breakdown of Value Sales for Hospital & Diagnostic Laboratories, Pharma & Biotech Companies and Research & Academic Institutes for the Years 2025 & 2030
• CANADA
  • TABLE 28: Canada Recent Past, Current & Future Analysis for Gene Panel by Application - Cancer Risk Assessment, Diagnosis of Congenital Diseases, Pharmacogenetics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 29: Canada 6-Year Perspective for Gene Panel by Application - Percentage Breakdown of Value Sales for Cancer Risk Assessment, Diagnosis of Congenital Diseases, Pharmacogenetics and Other Applications for the Years 2025 & 2030
  • TABLE 30: Canada Recent Past, Current & Future Analysis for Gene Panel by Product & Service - Test Kits and Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 31: Canada 6-Year Perspective for Gene Panel by Product & Service - Percentage Breakdown of Value Sales for Test Kits and Testing Services for the Years 2025 & 2030
  • TABLE 32: Canada Recent Past, Current & Future Analysis for Gene Panel by End-Use - Hospital & Diagnostic Laboratories, Pharma & Biotech Companies and Research & Academic Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: Canada 6-Year Perspective for Gene Panel by End-Use - Percentage Breakdown of Value Sales for Hospital & Diagnostic Laboratories, Pharma & Biotech Companies and Research & Academic Institutes for the Years 2025 & 2030
• JAPAN
  • Gene Panel Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 34: Japan Recent Past, Current & Future Analysis for Gene Panel by Application - Cancer Risk Assessment, Diagnosis of Congenital Diseases, Pharmacogenetics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 35: Japan 6-Year Perspective for Gene Panel by Application - Percentage Breakdown of Value Sales for Cancer Risk Assessment, Diagnosis of Congenital Diseases, Pharmacogenetics and Other Applications for the Years 2025 & 2030
  • TABLE 36: Japan Recent Past, Current & Future Analysis for Gene Panel by Product & Service - Test Kits and Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 37: Japan 6-Year Perspective for Gene Panel by Product & Service - Percentage Breakdown of Value Sales for Test Kits and Testing Services for the Years 2025 & 2030
  • TABLE 38: Japan Recent Past, Current & Future Analysis for Gene Panel by End-Use - Hospital & Diagnostic Laboratories, Pharma & Biotech Companies and Research & Academic Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Japan 6-Year Perspective for Gene Panel by End-Use - Percentage Breakdown of Value Sales for Hospital & Diagnostic Laboratories, Pharma & Biotech Companies and Research & Academic Institutes for the Years 2025 & 2030
• CHINA
  • Gene Panel Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 40: China Recent Past, Current & Future Analysis for Gene Panel by Application - Cancer Risk Assessment, Diagnosis of Congenital Diseases, Pharmacogenetics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 41: China 6-Year Perspective for Gene Panel by Application - Percentage Breakdown of Value Sales for Cancer Risk Assessment, Diagnosis of Congenital Diseases, Pharmacogenetics and Other Applications for the Years 2025 & 2030
  • TABLE 42: China Recent Past, Current & Future Analysis for Gene Panel by Product & Service - Test Kits and Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 43: China 6-Year Perspective for Gene Panel by Product & Service - Percentage Breakdown of Value Sales for Test Kits and Testing Services for the Years 2025 & 2030
  • TABLE 44: China Recent Past, Current & Future Analysis for Gene Panel by End-Use - Hospital & Diagnostic Laboratories, Pharma & Biotech Companies and Research & Academic Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: China 6-Year Perspective for Gene Panel by End-Use - Percentage Breakdown of Value Sales for Hospital & Diagnostic Laboratories, Pharma & Biotech Companies and Research & Academic Institutes for the Years 2025 & 2030
• EUROPE
  • Gene Panel Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 46: Europe Recent Past, Current & Future Analysis for Gene Panel by Application - Cancer Risk Assessment, Diagnosis of Congenital Diseases, Pharmacogenetics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 47: Europe 6-Year Perspective for Gene Panel by Application - Percentage Breakdown of Value Sales for Cancer Risk Assessment, Diagnosis of Congenital Diseases, Pharmacogenetics and Other Applications for the Years 2025 & 2030
  • TABLE 48: Europe Recent Past, Current & Future Analysis for Gene Panel by Product & Service - Test Kits and Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 49: Europe 6-Year Perspective for Gene Panel by Product & Service - Percentage Breakdown of Value Sales for Test Kits and Testing Services for the Years 2025 & 2030
  • TABLE 50: Europe Recent Past, Current & Future Analysis for Gene Panel by End-Use - Hospital & Diagnostic Laboratories, Pharma & Biotech Companies and Research & Academic Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Europe 6-Year Perspective for Gene Panel by End-Use - Percentage Breakdown of Value Sales for Hospital & Diagnostic Laboratories, Pharma & Biotech Companies and Research & Academic Institutes for the Years 2025 & 2030
  • TABLE 52: Europe Recent Past, Current & Future Analysis for Gene Panel by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 53: Europe 6-Year Perspective for Gene Panel by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
• FRANCE
  • Gene Panel Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 54: France Recent Past, Current & Future Analysis for Gene Panel by Application - Cancer Risk Assessment, Diagnosis of Congenital Diseases, Pharmacogenetics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 55: France 6-Year Perspective for Gene Panel by Application - Percentage Breakdown of Value Sales for Cancer Risk Assessment, Diagnosis of Congenital Diseases, Pharmacogenetics and Other Applications for the Years 2025 & 2030
  • TABLE 56: France Recent Past, Current & Future Analysis for Gene Panel by Product & Service - Test Kits and Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: France 6-Year Perspective for Gene Panel by Product & Service - Percentage Breakdown of Value Sales for Test Kits and Testing Services for the Years 2025 & 2030
  • TABLE 58: France Recent Past, Current & Future Analysis for Gene Panel by End-Use - Hospital & Diagnostic Laboratories, Pharma & Biotech Companies and Research & Academic Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 59: France 6-Year Perspective for Gene Panel by End-Use - Percentage Breakdown of Value Sales for Hospital & Diagnostic Laboratories, Pharma & Biotech Companies and Research & Academic Institutes for the Years 2025 & 2030
• GERMANY
  • Gene Panel Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 60: Germany Recent Past, Current & Future Analysis for Gene Panel by Application - Cancer Risk Assessment, Diagnosis of Congenital Diseases, Pharmacogenetics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 61: Germany 6-Year Perspective for Gene Panel by Application - Percentage Breakdown of Value Sales for Cancer Risk Assessment, Diagnosis of Congenital Diseases, Pharmacogenetics and Other Applications for the Years 2025 & 2030
  • TABLE 62: Germany Recent Past, Current & Future Analysis for Gene Panel by Product & Service - Test Kits and Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Germany 6-Year Perspective for Gene Panel by Product & Service - Percentage Breakdown of Value Sales for Test Kits and Testing Services for the Years 2025 & 2030
  • TABLE 64: Germany Recent Past, Current & Future Analysis for Gene Panel by End-Use - Hospital & Diagnostic Laboratories, Pharma & Biotech Companies and Research & Academic Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 65: Germany 6-Year Perspective for Gene Panel by End-Use - Percentage Breakdown of Value Sales for Hospital & Diagnostic Laboratories, Pharma & Biotech Companies and Research & Academic Institutes for the Years 2025 & 2030
• ITALY
  • TABLE 66: Italy Recent Past, Current & Future Analysis for Gene Panel by Application - Cancer Risk Assessment, Diagnosis of Congenital Diseases, Pharmacogenetics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 67: Italy 6-Year Perspective for Gene Panel by Application - Percentage Breakdown of Value Sales for Cancer Risk Assessment, Diagnosis of Congenital Diseases, Pharmacogenetics and Other Applications for the Years 2025 & 2030
  • TABLE 68: Italy Recent Past, Current & Future Analysis for Gene Panel by Product & Service - Test Kits and Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Italy 6-Year Perspective for Gene Panel by Product & Service - Percentage Breakdown of Value Sales for Test Kits and Testing Services for the Years 2025 & 2030
  • TABLE 70: Italy Recent Past, Current & Future Analysis for Gene Panel by End-Use - Hospital & Diagnostic Laboratories, Pharma & Biotech Companies and Research & Academic Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 71: Italy 6-Year Perspective for Gene Panel by End-Use - Percentage Breakdown of Value Sales for Hospital & Diagnostic Laboratories, Pharma & Biotech Companies and Research & Academic Institutes for the Years 2025 & 2030
• UNITED KINGDOM
  • Gene Panel Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 72: UK Recent Past, Current & Future Analysis for Gene Panel by Application - Cancer Risk Assessment, Diagnosis of Congenital Diseases, Pharmacogenetics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 73: UK 6-Year Perspective for Gene Panel by Application - Percentage Breakdown of Value Sales for Cancer Risk Assessment, Diagnosis of Congenital Diseases, Pharmacogenetics and Other Applications for the Years 2025 & 2030
  • TABLE 74: UK Recent Past, Current & Future Analysis for Gene Panel by Product & Service - Test Kits and Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: UK 6-Year Perspective for Gene Panel by Product & Service - Percentage Breakdown of Value Sales for Test Kits and Testing Services for the Years 2025 & 2030
  • TABLE 76: UK Recent Past, Current & Future Analysis for Gene Panel by End-Use - Hospital & Diagnostic Laboratories, Pharma & Biotech Companies and Research & Academic Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 77: UK 6-Year Perspective for Gene Panel by End-Use - Percentage Breakdown of Value Sales for Hospital & Diagnostic Laboratories, Pharma & Biotech Companies and Research & Academic Institutes for the Years 2025 & 2030
• REST OF EUROPE
  • TABLE 78: Rest of Europe Recent Past, Current & Future Analysis for Gene Panel by Application - Cancer Risk Assessment, Diagnosis of Congenital Diseases, Pharmacogenetics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 79: Rest of Europe 6-Year Perspective for Gene Panel by Application - Percentage Breakdown of Value Sales for Cancer Risk Assessment, Diagnosis of Congenital Diseases, Pharmacogenetics and Other Applications for the Years 2025 & 2030
  • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Gene Panel by Product & Service - Test Kits and Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Rest of Europe 6-Year Perspective for Gene Panel by Product & Service - Percentage Breakdown of Value Sales for Test Kits and Testing Services for the Years 2025 & 2030
  • TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for Gene Panel by End-Use - Hospital & Diagnostic Laboratories, Pharma & Biotech Companies and Research & Academic Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 83: Rest of Europe 6-Year Perspective for Gene Panel by End-Use - Percentage Breakdown of Value Sales for Hospital & Diagnostic Laboratories, Pharma & Biotech Companies and Research & Academic Institutes for the Years 2025 & 2030
• ASIA-PACIFIC
  • Gene Panel Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 84: Asia-Pacific Recent Past, Current & Future Analysis for Gene Panel by Application - Cancer Risk Assessment, Diagnosis of Congenital Diseases, Pharmacogenetics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 85: Asia-Pacific 6-Year Perspective for Gene Panel by Application - Percentage Breakdown of Value Sales for Cancer Risk Assessment, Diagnosis of Congenital Diseases, Pharmacogenetics and Other Applications for the Years 2025 & 2030
  • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Gene Panel by Product & Service - Test Kits and Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Asia-Pacific 6-Year Perspective for Gene Panel by Product & Service - Percentage Breakdown of Value Sales for Test Kits and Testing Services for the Years 2025 & 2030
  • TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for Gene Panel by End-Use - Hospital & Diagnostic Laboratories, Pharma & Biotech Companies and Research & Academic Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 89: Asia-Pacific 6-Year Perspective for Gene Panel by End-Use - Percentage Breakdown of Value Sales for Hospital & Diagnostic Laboratories, Pharma & Biotech Companies and Research & Academic Institutes for the Years 2025 & 2030
• REST OF WORLD
  • TABLE 90: Rest of World Recent Past, Current & Future Analysis for Gene Panel by Application - Cancer Risk Assessment, Diagnosis of Congenital Diseases, Pharmacogenetics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 91: Rest of World 6-Year Perspective for Gene Panel by Application - Percentage Breakdown of Value Sales for Cancer Risk Assessment, Diagnosis of Congenital Diseases, Pharmacogenetics and Other Applications for the Years 2025 & 2030
  • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Gene Panel by Product & Service - Test Kits and Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Rest of World 6-Year Perspective for Gene Panel by Product & Service - Percentage Breakdown of Value Sales for Test Kits and Testing Services for the Years 2025 & 2030
  • TABLE 94: Rest of World Recent Past, Current & Future Analysis for Gene Panel by End-Use - Hospital & Diagnostic Laboratories, Pharma & Biotech Companies and Research & Academic Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 95: Rest of World 6-Year Perspective for Gene Panel by End-Use - Percentage Breakdown of Value Sales for Hospital & Diagnostic Laboratories, Pharma & Biotech Companies and Research & Academic Institutes for the Years 2025 & 2030

IV. COMPETITION